白血球分離療法市場規模、シェア、動向、2031年までの世界予測

白血球分離療法市場は、2026年には9,060万米ドル規模と推定され、2031年には1億3,870万米ドルに達すると予測されており、年平均成長率（CAGR）は8.9%です。白血球パック市場は、2026年には4億3,210万米ドル規模と推定され、2031年には18億8,390万米ドルに成長し、年平均成長率（CAGR）は34.2%に達するとMarketsandMarketsでは予測しています。

この成長は、白血球アフェレーシス手技、臨床意思決定、および高度な細胞採取ワークフローの未来を形作るいくつかの重要な要因によって推進されています。

血液疾患の増加と、細胞・遺伝子治療の開発および治療介入を促進するための高品質な白血球採取の必要性の高まりが、成長を牽引し続ける主な要因です。CAR-T細胞療法、TCR療法、NK細胞療法、その他の免疫療法の利用が増加するにつれ、病院、血液センター、アフェレーシス施設は、自動制御、連続フロープラットフォーム、GMP準拠の使い捨て製品を備えた高度な白血球アフェレーシスシステムを導入することで、白血球アフェレーシス能力を急速に向上させています。これにより、採取精度の向上、細胞生存率の維持、そしてタイムリーな臨床介入の実現が可能になります。

調査範囲

本市場調査は、白血球分離療法（白血球アフェレーシス／白血球除去療法）市場を様々なセグメントに分けて分析しています。市場規模と成長可能性を、タイプ別、用途別、エンドユーザー別、地域別に推定することを目的としています。また、主要企業の詳細な競合分析、企業プロファイル、製品および事業内容に関する重要な考察、最近の動向、主要な市場戦略についても詳述しています。

本レポートを購入する理由

本レポートは、既存企業はもちろん、新規参入企業や中小企業にとっても、市場動向を理解し、より大きな市場シェアを獲得するのに役立ちます。本レポートを購入した企業は、以下に概説する5つの戦略のうち、1つ以上を実行することができます。

本レポートでは、以下の点について考察します。

• 主要な推進要因、阻害要因、機会、課題の分析
• 製品開発／イノベーション：白血球分離療法（白血球アフェレーシス／白血球除去療法）市場における今後の技術および製品発売に関する詳細な分析
• 市場開発：有望な新興市場に関する包括的な情報
• 市場の多様化：白血球分離療法（白血球アフェレーシス／白血球除去療法）市場における製品、未開拓地域、最近の動向、投資に関する詳細な情報
• 競合評価：白血球分離療法市場における主要企業の市場シェア、戦略、製品、流通ネットワーク、製造能力に関する詳細な評価

Report Description

The leukapheresis market was estimated to be worth USD 90.6 million in 2026 and is poised to reach USD 138.7 million by 2031, growing at a CAGR of 8.9%. The leukopaks market was estimated to be worth USD 432.1 million in 2026 and is poised to reach USD 1,883.9 million by 2031, growing at a CAGR of 34.2%.

This growth is driven by several key factors shaping the future of leukapheresis procedures, clinical decision-making, and advanced cell-collection workflows.

The rising number of hematologic disorders and the increasing need for high-quality leukocyte collections to facilitate cell and gene therapy development and therapeutic interventions are the main factors that continue to drive growth. With the increasing use of CAR-T, TCR, NK cell therapies, and other immunotherapies, hospitals, blood centers, and apheresis units are rapidly upgrading their leukapheresis capabilities by acquiring advanced leukapheresis systems that feature automated controls, continuous, flow platforms, and GMP, compliant disposables, which help them to improve collection accuracy, maintain cell viability, and achieve timely clinical interventions.

On top of that, the increasing incidence of hematologic disorders, autoimmune diseases, and immune-mediated conditions is driving up the demand for high-quality leukocyte collections. Hospitals and research centers are leaning toward advanced leukapheresis modalities, such as continuous, flow apheresis systems, membrane-based separators, and automated GMP-compliant platforms, as they are more precise, efficient, and scalable for cell collection.

Also, the market expansion is being spurred by the transition toward digital apheresis workflows, which include electronic documentation, donor-monitoring systems, and integrated data platforms. This shift not only helps in procedure standardization but also enables remote monitoring and connectivity with cell therapy manufacturing records. Besides that, technological advances, including AI, assisted cell, quality assessment, predictive analytics, and cloud-based workflow management, are playing a part in the market growth. They increase the efficiency of collection, traceability, and usability, thus providing advanced leukapheresis solutions with increased practicality in diverse clinical and research settings, ranging from large hospitals to standalone apheresis centers.

“The disposables segment is projected to record the fastest growth by type during the forecast period.”

Globally, the disposables segment dominated the leukapheresis market in 2025, primarily due to the increasing emphasis on standardized workflows, strict sterilization practices, and robust traceability requirements in healthcare systems. These factors collectively amplified the demand for single-use consumables. Disposables are essential in cell and gene therapy–related collections, where maintaining process uniformity, preventing contamination, and ensuring accurate documentation are critical. With the rapid global expansion of CGT manufacturing, including CAR-T, TCR-T, and stem-cell programs, the need for single-use kits, tubing sets, collection bags, filters, and closed-system consumables continues to rise steadily.

“The academic & research institutes segment accounted for the largest share of the leukopaks market.”

By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2025, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.

“Asia Pacific is projected to witness the highest growth during the forecast period.”

During the forecast period, the Asia Pacific region is expected to record the highest growth rate in the leukapheresis market. Some of the major reasons that work toward the growth of the market are the rising cases of hematologic disorders, the increasing use of cell and gene therapy, the development of apheresis infrastructure, and the growing investment in advanced therapeutic technologies by regional as well as global players. Moreover, the region benefits from increased public awareness of novel treatment modalities, healthcare access enhancement, rapid growth of specialty hospitals and blood transfusion centers, and higher involvement in CGT-related clinical trials. Altogether, these elements will stimulate the demand for leukapheresis procedures and consumables in Asia Pacific countries.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
• By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By End User: Academic & Research Institutes (45%), Pharmaceutical & Biotechnology Companies (30%), Contract Research Organizations (25%)
• By Designation: Apheresis Nurses & Practitioners (47%), Hematologists/Oncologists(22%), GMP Facility Heads (15%), and Others (16%)
• By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the leukapheresis market in various segments. It aims to estimate the market size and growth potential of this market by type, application, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

• Analysis of key drivers, restraints, opportunities, and challenges
• Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the leukapheresis market
• Market Development: Comprehensive information about lucrative emerging markets
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the leukapheresis market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the leukapheresis market

Table of Contents

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 STUDY SCOPE 33
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 33
1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY 34
1.3.3 YEARS CONSIDERED 35
1.4 CURRENCY CONSIDERED 35
1.5 STAKEHOLDERS 36
1.6 SUMMARY OF CHANGES 36
2 EXECUTIVE SUMMARY 38
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 38
2.2 LEUKOPAKS MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 39
2.3 LEUKAPHERESIS MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 40
2.4 DISRUPTIVE TRENDS IN LEUKAPHERESIS MARKET 41
2.5 HIGH-GROWTH SEGMENTS 42
2.6 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 43
3 PREMIUM INSIGHTS 45
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN LEUKAPHERESIS MARKET 45
3.2 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER AND COUNTRY 46
3.3 GEOGRAPHIC SNAPSHOT OF LEUKAPHERSIS MARKET 47
3.4 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN LEUKOPAKS MARKET 48
3.5 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE AND COUNTRY 49
3.6 GEOGRAPHIC SNAPSHOT OF LEUKOPAKS MARKET 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 52
4.2.1.1 Rising utilization of leukopaks in CAR-T cell therapy development 52
4.2.1.2 Increasing incidence and clinical burden of leukemia 52
4.2.1.3 Leukopaks and leukapheresis driving advances in research & development activities 54
4.2.1.4 Leukopaks as key contributors to CAR-T cell therapy clinical trials 54
4.2.2 RESTRAINTS 55
4.2.2.1 Elevated costs of therapeutic leukapheresis and leukopak products 55
4.2.2.2 Limited donor availability and stringent screening criteria for leukapheresis 56
4.2.2.3 Shortage of skilled healthcare professionals in apheresis and cell therapy procedures 57
4.2.2.4 Complications associated with therapeutic leukapheresis 57
4.2.3 OPPORTUNITIES 58
4.2.3.1 Increasing focus on leukapheresis in pediatric patients 58
4.2.3.2 Rise in investments in CAR-T therapies in emerging economies 58
4.2.3.3 Gaps in current leukapheresis technologies 59
4.2.4 CHALLENGES 59
4.2.4.1 Infectious disease risks related to safety of blood transfusion in emerging economies 59
4.2.4.2 Donor variability and inconsistent leukopak quality 60
4.3 UNMET NEEDS & WHITE SPACES 60
4.3.1 UNMET NEEDS IN LEUKAPHERESIS MARKET 60
4.3.2 WHITE SPACE OPPORTUNITIES 61
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 63
4.4.1 INTERCONNECTED MARKETS 63
4.4.2 CROSS-SECTOR OPPORTUNITIES 63
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64
4.5.1 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS IN LEUKAPHERESIS MARKET 64
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 67
5.1.3 BARGAINING POWER OF SUPPLIERS 67
5.1.4 BARGAINING POWER OF BUYERS 67
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS & FORECAST 68
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 69
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 69
5.3 SUPPLY CHAIN ANALYSIS 70
5.4 VALUE CHAIN ANALYSIS 71
5.5 MARKET ECOSYSTEM 73
5.5.1 LEUKAPHERESIS MARKET PROVIDERS 74
5.5.2 END USERS 75
5.5.3 REGULATORY BODIES 76
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET) 76
5.6.1 AVERAGE SELLING PRICE TREND FOR NON-MOBILIZED LEUKOPAKS,
BY REGION, 2023–2025 (USD) 79
5.6.2 AVERAGE SELLING PRICE TREND FOR MOBILIZED LEUKOPAKS, BY REGION, 2023–2025 (USD) 79
5.7 TRADE ANALYSIS 80
5.7.1 IMPORT DATA FOR HS CODE 901890 80
5.7.2 EXPORT DATA FOR HS CODE 901890 80
5.8 REIMBURSEMENT SCENARIO 81
5.9 KEY CONFERENCES & EVENTS (2026–2027) 82
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 83
5.11 INVESTMENT & FUNDING SCENARIO 84
5.12 CASE STUDY ANALYSIS 85
5.13 IMPACT OF 2025 US TARIFF ON LEUKAPHERESIS MARKET 87
5.13.1 INTRODUCTION 87
5.13.2 KEY TARIFF RATES 88
5.13.3 PRICE IMPACT ANALYSIS 88
5.13.4 IMPACT ON REGIONS 89
5.13.5 IMPACT ON END-USE SEGMENTS 91
5.13.5.1 Leukapheresis 91
5.13.5.2 Leukopaks 92
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE IMPACT, PATENTS, AND INNOVATIONS 93
6.1 TECHNOLOGY ANALYSIS 93
6.1.1 KEY EMERGING TECHNOLOGIES 93
6.1.1.1 Automated & AI-enabled apheresis systems 93
6.1.1.2 Closed-loop & GMP-compliant processing systems 93
6.1.1.3 Cryopreservation & cryo-processed leukopaks technologies 94
6.1.2 COMPLEMENTARY TECHNOLOGIES 94
6.1.2.1 Cell processing & manufacturing platforms (CGT ecosystem) 94
6.1.2.2 Digital monitoring, data integration, and workflow software 95
6.1.3 ADJACENT TECHNOLOGIES 95
6.1.3.1 Regenerative medicine & stem cell technologies 95
6.2 TECHNOLOGY/PRODUCT ROADMAP 96
6.2.1 NEAR TERM (2025–2027) 96
6.2.2 MID TERM (2028–2030) 96
6.2.3 LONG TERM (2030+) 97
6.3 PATENT ANALYSIS 97
6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS 97
6.4 FUTURE APPLICATIONS 99
6.4.1 CELL & GENE THERAPY (CAR-T, TCR, NK CELLS) 99
6.4.2 DECENTRALIZED & POINT-OF-CARE CELL COLLECTION 99
6.4.3 STEM CELL TRANSPLANTATION & REGENERATIVE MEDICINE 100

6.5 IMPACT OF AI/GEN AI ON LEUKAPHERESIS MARKET 100
6.5.1 INTRODUCTION 100
6.5.2 MARKET POTENTIAL OF AI IN LEUKAPHERESIS 100
6.5.3 AI USE CASES 101
6.5.4 KEY COMPANIES IMPLEMENTING AI 102
7 SUSTAINABILITY & REGULATORY BEHAVIOR 103
7.1 REGULATORY LANDSCAPE 103
7.1.1 REGULATORY FRAMEWORK 103
7.1.1.1 North America 103
7.1.1.2 Europe 103
7.1.1.3 Asia Pacific 103
7.1.1.4 Latin America 104
7.1.1.5 Middle East & Africa 104
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.1.3 INDUSTRY STANDARDS 107
7.2 SUSTAINABILITY INITIATIVES 108
7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR LEUKAPHERESIS 108
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 109
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 109
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110
8.1 KEY STAKEHOLDERS & BUYING CRITERIA 110
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
8.1.2 BUYING CRITERIA 111
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 111
8.2.1 DECISION-MAKING PROCESS 111
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
8.2.4 MARKET PROFITABILITY 114
9 LEUKAPHERESIS MARKET, BY PRODUCT TYPE 115
9.1 INTRODUCTION 116
9.2 DISPOSABLES 116
9.2.1 SINGLE-USE, PROCEDURE-DRIVEN CONSUMPTION TO BOOST SEGMENT 116
9.2.2 TUBING SETS & COLLECTION BAGS 118
9.2.2.1 Rising leukapheresis procedure volumes driving demand for tubing sets & collection bags 118
9.2.3 FILTERS & MEMBRANE CONSUMABLES 119
9.2.3.1 Growing adoption of leukocyte removal filters in inflammatory disease management 119

9.2.4 COLLECTION KITS & ACCESSORIES 121
9.2.4.1 Increasing leukapheresis and leukopak collection activities driving demand for collection kits and accessories 121
9.3 DEVICES 123
9.3.1 CENTRIFUGAL DEVICES 124
9.3.1.1 Increasing installation in hospitals to drive market 124
9.3.1.2 Global volume analysis: Centrifugal devices market (2024–2031) 126
9.3.2 MEMBRANE SEPARATORS 127
9.3.2.1 Difficulty in separating large volumes of plasma to limit market 127
10 LEUKAPHERESIS MARKET, BY APPLICATION 129
10.1 INTRODUCTION 130
10.2 RESEARCH APPLICATIONS 130
10.2.1 EXPANDING CELL & GENE THERAPY PIPELINE TO DRIVE THE SEGMENT 130
10.3 THERAPEUTIC APPLICATIONS 132
10.3.1 INCREASING ADOPTION OF LEUKAPHERESIS IN LEUKEMIA MANAGEMENT DRIVING MARKET GROWTH 132
11 LEUKAPHERESIS MARKET, BY END USER 134
11.1 INTRODUCTION 135
11.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 135
11.2.1 RISING BLOOD DONATION AND TRANSFUSION NEEDS DRIVING LEUKAPHERESIS DEMAND 135
11.3 HOSPITALS & TRANSFUSION CENTERS 137
11.3.1 HIGH PROCEDURAL VOLUMES IN HOSPITALS TO DRIVE LEUKAPHERESIS DEMAND 137
11.4 ACADEMIC & RESEARCH INSTITUTES 139
11.4.1 INCREASING ACADEMIC–INDUSTRY COLLABORATIONS TO BOOST MARKET 139
11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 140
11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO BOOST SEGMENT 140
12 LEUKOPAKS MARKET, BY TYPE 143
12.1 INTRODUCTION 144
12.2 MOBILIZED LEUKOPAKS 146
12.2.1 INCREASING USE OF MOBILIZED LEUKOPAKS IN CLINICAL RESEARCH TO DRIVE MARKET 146
12.2.2 GLOBAL VOLUME ANALYSIS: MOBILIZED LEUKOPAKS MARKET (2024–2031) 148
12.3 NON-MOBILIZED LEUKOPAKS 148
12.3.1 ADOPTION OF NON-MOBILIZED LEUKOPAKS DRIVEN BY LOWER COST AND CELL YIELD 148
12.3.2 GLOBAL VOLUME ANALYSIS: NON-MOBILIZED LEUKOPAKS MARKET (2024–2031) 151
12.4 DISEASED LEUKOPAKS 151
12.4.1 INCREASING DEMAND FOR DISEASE-STATE LEUKOPAKS IN ADVANCED THERAPEUTIC RESEARCH DRIVING MARKET GROWTH” 151
12.4.2 GLOBAL VOLUME ANALYSIS: DISEASED LEUKOPAKS MARKET (2024–2031) 153
12.5 ISOLATED PBMCS 153
12.5.1 INCREASING RESEARCH FOCUS ON CELL-BASED THERAPIES TO FUEL MARKET 153
12.5.2 GLOBAL VOLUME ANALYSIS: ISOLATED PBMCS MARKET (2024–2031) 156
13 LEUKOPAKS MARKET, BY INDICATION 157
13.1 INTRODUCTION 158
13.2 ACUTE LYMPHOCYTIC LEUKEMIA 159
13.2.1 INCREASING INCIDENCE OF ACUTE LYMPHOCYTIC LEUKEMIA SUPPORTING MARKET GROWTH 159
13.3 MULTIPLE MYELOMA 161
13.3.1 RISING MULTIPLE MYELOMA CASES DRIVING MARKET EXPANSION 161
13.4 NON-HODGKIN’S LYMPHOMA 162
13.4.1 DEVELOPMENT OF NOVEL THERAPIES TO BOOST MARKET 162
13.5 CHRONIC LYMPHOCYTIC LEUKEMIA 164
13.5.1 GROWING PREVALENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA DRIVING SEGMENT EXPANSION 164
13.6 PANCREATIC CANCER 165
13.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO DRIVE SEGMENT 165
13.7 HEPATOCELLULAR CARCINOMA 167
13.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS TO FUEL SEGMENT 167
13.8 OTHER INDICATIONS 168
14 LEUKOPAKS MARKET, BY END USER 170
14.1 INTRODUCTION 171
14.2 ACADEMIC & RESEARCH INSTITUTES 172
14.2.1 INCREASING INDUSTRY–ACADEMIC COLLABORATIONS DRIVING MARKET GROWTH 172
14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 173
14.3.1 RISING DEMAND FOR TARGETED CELL-BASED DRUG DEVELOPMENT DRIVING LEUKOPAK ADOPTION 173
14.4 CONTRACT RESEARCH ORGANIZATIONS 174
14.4.1 INCREASING CRO-LED CLINICAL ACTIVITIES DRIVING DEMAND FOR LEUKAPHERESIS-DERIVED MATERIALS 174
15 LEUKAPHERESIS MARKET, BY REGION 177
15.1 INTRODUCTION 178
15.2 NORTH AMERICA 179
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 180
15.2.2 NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 184
15.2.3 US 184
15.2.3.1 Strong Presence of Biopharmaceutical Leaders and Expanding Cell Therapy Ecosystem Driving Market Growth 184
15.2.4 CANADA 188
15.2.4.1 Increasing Leukemia Incidence and Advancements in CAR-T Therapies Supporting Market Growth in Canada 188
15.3 EUROPE 191
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 192
15.3.2 EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 196
15.3.3 GERMANY 196
15.3.3.1 Rising Healthcare Expenditure, Expanding Academic–Clinical Cell Therapy Ecosystem to drive market growth 196
15.3.4 UK 199
15.3.4.1 Expanding Apheresis Capacity and CAR-T Therapies Adoption to support market growth 199
15.3.1 FRANCE 202
15.3.1.1 Centralized CAR-T Delivery System and Strong Public Reimbursement to propel market growth 202
15.3.2 ITALY 205
15.3.2.1 Rising elderly patient pool and high cancer incidence to drive market growth 205
15.3.3 SPAIN 208
15.3.3.1 Rising Hematologic Cancer Burden to support market growth 208
15.3.4 BELGIUM 209
15.3.4.1 Strong Clinical Research Ecosystem and Structured Reimbursement Framework to boost the market 209
15.3.5 NETHERLANDS 209
15.3.5.1 Strong healthcare infrastructure and aging population to drive market 209
15.3.6 POLAND 212
15.3.6.1 Rise in cancer incidence to boost the market 212
15.3.7 SWITZERLAND 214
15.3.7.1 Early adoption of cell therapies to drive market demand 214
15.3.8 REST OF EUROPE 217
15.4 ASIA PACIFIC 220
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 221
15.4.2 ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 226
15.4.3 CHINA 227
15.4.3.1 Increasing hematologic cancer burden, CAR-T expansion, and biotech investments driving leukapheresis growth in China 227
15.4.4 JAPAN 230
15.4.4.1 Moderate-to-high healthcare expenditure supporting leukapheresis market growth 230
15.4.5 INDIA 234
15.4.5.1 Rising government investment in healthcare to drive market growth 234
15.4.6 AUSTRALIA 237
15.4.6.1 Clinical integration of CAR-T therapies in hospitals as core growth driver for leukapheresis in Australia 237
15.4.7 SOUTH KOREA 241
15.4.7.1 Integration of digital and automated cell processing technologies driving growth in the leukapheresis market 241
15.4.8 NEW ZEALAND 245
15.4.8.1 Strengthening therapeutic apheresis infrastructure as a core growth driver for the New Zealand leukapheresis market 245
15.4.9 THAILAND 248
15.4.9.1 Rising oncology demand for cell-based therapies driving leukapheresis market growth 248
15.4.10 REST OF ASIA PACIFIC 251
15.5 LATIN AMERICA 254
15.5.1 LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 258
15.5.2 BRAZIL 258
15.5.2.1 Role of blood donation, transplant activity, and cell therapy expansion in driving the leukapheresis and leukopak market 258
15.5.3 MEXICO 261
15.5.3.1 Emerging CAR-T therapy and cost-driven leukemia care market in Mexico 261
15.5.4 REST OF LATIN AMERICA 264
15.6 MIDDLE EAST & AFRICA 267
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 268
15.6.2 MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE (2024–2031) 272
15.6.3 GCC COUNTRIES 272
15.6.3.1 Kingdom of Saudi Arabia (KSA) 272
15.6.3.1.1 Transforming clinical research in Saudi Arabia through healthcare innovation initiatives 272
15.6.3.2 United Arab Emirates (UAE) 275
15.6.3.2.1 Emergence as a Regional Hub for Advanced Precision Medicine 275
15.6.3.3 Other GCC countries 278
15.6.4 REST OF MIDDLE EAST & AFRICA 281
16 COMPETITIVE LANDSCAPE 285
16.1 INTRODUCTION 285
16.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022–2026 285
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET 286
16.3 REVENUE ANALYSIS, 2023–2025 288
16.3.1 LEUKAPHERESIS MARKET: REVENUE ANALYSIS 288
16.3.2 LEUKOPAKS MARKET: REVENUE ANALYSIS 289
16.4 MARKET SHARE ANALYSIS, 2025 290
16.4.1 LEUKAPHERESIS MARKET: SHARE ANALYSIS 290
16.4.2 LEUKOPAKS MARKET: SHARE ANALYSIS 291

16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 292
16.5.1 LEUKOPAKS MARKET 292
16.5.1.1 Stars 292
16.5.1.2 Emerging leaders 292
16.5.1.3 Pervasive players 292
16.5.1.4 Participants 292
16.5.1.5 Company footprint: Key players, 2025 294
16.5.1.5.1 Company footprint 294
16.5.1.5.2 By Region footprint 294
16.5.1.5.3 By product type footprint 295
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 295
16.6.1 LEUKOPAKS MARKET 295
16.6.1.1 Progressive companies 295
16.6.1.2 Responsive companies 295
16.6.1.3 Dynamic companies 295
16.6.1.4 Starting blocks 296
16.6.1.5 Competitive benchmarking: Startups/SMEs, 2025 297
16.6.1.5.1 Detailed list of key startups/SMEs 297
16.6.1.5.2 Competitive benchmarking of key startups/SMEs 298
16.7 COMPANY VALUATION AND FINANCIAL METRICS 298
16.7.1 FINANCIAL METRICS: LEUKAPHERESIS MARKET 298
16.7.2 COMPANY VALUATION : LEUKAPHERESIS MARKET 299
16.7.3 FINANCIAL METRICS: LEUKOPAKS MARKET 299
16.7.4 COMPANY VALUATION: LEUKOPAKS MARKET 300
16.8 LEUKOPAKS BRAND/PRODUCT COMPARISON 301
16.9 LEUKAPHEREIS BRAND/PRODUCT COMPARISON 302
16.10 COMPETITIVE SCENARIO 303
16.10.1 LEUKAPHERESIS MARKET 303
16.10.1.1 Product launches & approvals 303
16.10.1.2 Deals 304
16.10.1.3 Expansions 305
16.10.2 LEUKOPAKS MARKET 305
16.10.2.1 Product launches & approvals 305
16.10.2.2 Deals 307
16.10.2.3 Expansions 309
17 COMPANY PROFILES 311
17.1 LEUKAPHERESIS PRODUCTS MARKET: KEY PLAYERS 311
17.1.1 TERUMO CORPORATION 311
17.1.1.1 Business overview 311
17.1.1.2 Products offered 312
17.1.1.3 Recent developments 314
17.1.1.3.1 Product launches & approvals 314
17.1.1.3.2 Deals 314
17.1.1.3.3 Expansions 315
17.1.1.4 MnM view 315
17.1.1.4.1 Right to win 315
17.1.1.4.2 Strategic choices 316
17.1.1.4.3 Weaknesses & competitive threats 316
17.1.2 FRESENIUS SE & CO. KGAA 317
17.1.2.1 Business overview 317
17.1.2.2 Products offered 318
17.1.2.3 Recent developments 319
17.1.2.3.1 Product launches & approvals 319
17.1.2.3.2 Deals 320
17.1.2.3.3 Other developments 320
17.1.2.4 MnM view 320
17.1.2.4.1 Right to win 320
17.1.2.4.2 Strategic choices 320
17.1.2.4.3 Weaknesses & competitive threats 321
17.1.3 HAEMONETICS CORPORATION 322
17.1.3.1 Business overview 322
17.1.3.2 Products offered 323
17.1.3.3 Recent developments 326
17.1.3.3.1 Product launches & approvals 326
17.1.3.3.2 Deals 326
17.1.3.4 MnM view 326
17.1.3.4.1 Right to win 326
17.1.3.4.2 Strategic choices 326
17.1.3.4.3 Weaknesses & competitive threats 327
17.1.4 NIKKISO CO., LTD. 328
17.1.4.1 Business overview 328
17.1.4.2 Products offered 329
17.1.4.3 Recent developments 330
17.1.4.3.1 Other developments 330
17.1.4.4 MnM view 330
17.1.4.4.1 Right to win 330
17.1.4.4.2 Strategic choices 330
17.1.4.4.3 Weaknesses & competitive threats 330
17.1.5 SUMITOMO BAKELITE CO., LTD. 331
17.1.5.1 Business overview 331
17.1.5.2 Products offered 332
17.1.5.3 MnM view 333
17.1.5.3.1 Right to win 333
17.1.5.3.2 Strategic choices 333
17.1.5.3.3 Weaknesses & competitive threats 333
17.1.6 DANAHER CORPORATION 334
17.1.6.1 Business overview 334
17.1.6.2 Products offered 335
17.1.7 OTSUKA HOLDINGS CO., LTD. 336
17.1.7.1 Business overview 336
17.1.7.2 Products offered 337
17.1.8 ASAHI KASEI MEDICAL CO., LTD. 338
17.1.8.1 Business overview 338
17.1.8.2 Products offered 338
17.1.8.3 Recent developments 339
17.1.8.3.1 Other developments 339
17.1.9 MACOPHARMA SA 340
17.1.9.1 Business overview 340
17.1.9.2 Products offered 340
17.1.10 MEDICA SPA 342
17.1.10.1 Business overview 342
17.1.10.2 Products offered 342
17.2 LEUKAPHERESIS PRODUCTS MARKET: OTHER PLAYERS 343
17.2.1 POLYMED 343
17.2.2 PURIBLOOD MEDICAL 344
17.2.3 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD. 345
17.2.4 SAFETRAN BIOMEDICAL INC. 346
17.2.5 MITRA INDUSTRIES PRIVATE LIMITED 347
17.3 LEUKOPAKS MARKET: KEY PLAYERS 348
17.3.1 LONZA 348
17.3.1.1 Business overview 348
17.3.1.2 Products offered 349
17.3.1.3 Recent developments 351
17.3.1.3.1 Deals 351
17.3.1.4 MnM view 351
17.3.1.4.1 Right to win 351
17.3.1.4.2 Strategic choices 351
17.3.1.4.3 Weaknesses and competitive threats 351
17.3.2 GRIFOLS 352
17.3.2.1 Business overview 352
17.3.2.2 Products offered 353
17.3.3 CHARLES RIVER LABORATORIES 355
17.3.3.1 Business overview 355
17.3.3.2 Products offered 356
17.3.3.3 Recent developments 358
17.3.3.3.1 Product launches & approvals 358
17.3.3.3.2 Deals 358
17.3.3.3.3 Expansions 359
17.3.4 CELLEX CELL PROFESSIONALS 360
17.3.4.1 Business overview 360
17.3.4.2 Products offered 361
17.3.4.3 Recent developments 361
17.3.4.3.1 Deals 361
17.3.4.3.2 Expansions 362
17.3.5 STEMCELL TECHNOLOGIES 363
17.3.5.1 Business overview 363
17.3.5.2 Products offered 363
17.3.6 BIOIVT 365
17.3.6.1 Business overview 365
17.3.6.2 Products offered 365
17.3.6.3 Recent developments 367
17.3.6.3.1 Product launches & approvals 367
17.3.6.3.2 Deals 367
17.3.6.3.3 Expansions 367
17.3.7 DISCOVERY LIFE SCIENCES 368
17.3.7.1 Business overview 368
17.3.7.2 Products offered 368
17.3.7.3 Recent developments 370
17.3.7.3.1 Product launches & approvals 370
17.3.7.3.2 Deals 370
17.3.7.3.3 Expansions 370
17.3.8 MILTENYI BIOTEC 371
17.3.8.1 Business overview 371
17.3.8.2 Products offered 372
17.3.9 STEMVIVO INC. 373
17.3.9.1 Business overview 373
17.3.9.2 Products offered 374
17.3.10 CGT GLOBAL 375
17.3.10.1 Business overview 375
17.3.10.2 Products offered 375
17.3.10.3 Recent developments 377
17.3.10.3.1 Product launches & approvals 377
17.3.11 SANGUINE BIOSCIENCES 378
17.3.11.1 Business overview 378
17.3.11.2 Products offered 378
17.3.11.3 Recent developments 379
17.3.11.3.1 Product launches & approvals 379
17.4 LEUKOPAKS MARKET: OTHER PLAYERS 380
17.4.1 BIOMEX GMBH 380
17.4.2 ACCEGEN 381
17.4.3 EXCELLOS 382
17.4.4 FIRST CHOICE BIO INC. 383
17.4.5 ORGANA BIO 384
17.4.6 HUMAN CELLS BIO 384
18 RESEARCH METHODOLOGY 386
18.1 RESEARCH DATA 386
18.1.1 SECONDARY DATA 387
18.1.1.1 Key data from secondary sources 388
18.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET 391
18.3 MARKET GROWTH RATE PROJECTIONS 394
18.4 DATA TRIANGULATION 396
18.5 RESEARCH ASSUMPTIONS 397
18.5.1 GROWTH RATE ASSUMPTIONS 398
18.6 RISK ASSESSMENT 398
18.7 LIMITATIONS 399
18.7.1 METHODOLOGY-RELATED LIMITATIONS 399
18.7.2 SCOPE-RELATED LIMITATIONS 399
18.8 RESEARCH LIMITATIONS 399
18.9 RISK ANALYSIS 400
19 APPENDIX 401
19.1 DISCUSSION GUIDE 401
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 406
19.3 CUSTOMIZATION OPTIONS 408
19.3.1 COMPANY INFORMATION 408
19.3.2 GEOGRAPHIC ANALYSIS 408
19.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 408
19.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 408
19.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 408
19.4 RELATED REPORTS 409
19.5 AUTHOR DETAILS 410

LIST OF TABLES

TABLE 1 LEUKAPHERESIS MARKET: INCLUSIONS & EXCLUSIONS 34
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
TABLE 3 COST OF LEUKOPAKS, BY TYPE 55
TABLE 4 DONOR SELECTION CRITERIA 56
TABLE 5 FREQUENCY OF BLOOD DONATION FROM HEALTHY DONORS 57
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 68
TABLE 8 LIST OF KEY LEUKAPHERESIS DEVICES + DISPOSABLES MANUFACTURERS 74
TABLE 9 LIST OF KEY LEUKOPAKS MANUFACTURERS 75
TABLE 10 LIST OF KEY END USERS 75
TABLE 11 LIST OF KEY REGULATORY BODIES 76
TABLE 12 AVERAGE SELLING PRICE OF NON-MOBILIZED LEUKOPAKS, 2025 (USD) 77
TABLE 13 AVERAGE SELLING PRICE OF MOBILIZED LEUKOPAKS, 2025 (USD) 77
TABLE 14 AVERAGE SELLING PRICE OF DISEASED LEUKOPAKS, 2025 (USD) 78
TABLE 15 AVERAGE SELLING PRICE OF ISOLATED PBMCS, 2025 (USD) 78
TABLE 16 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80
TABLE 17 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80
TABLE 18 LEUKAPHERESIS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 82
TABLE 19 CASE STUDY 1: RAPID CYTOREDUCTION IN PEDIATRIC ACUTE LEUKEMIA USING LEUKAPHERESIS 85
TABLE 20 CASE STUDY 2: GLOBAL CELL THERAPY TRIAL ENABLED BY LEUKAPHERESIS INTEGRATION 86
TABLE 21 CASE STUDY 3: THERAPEUTIC LEUKAPHERESIS IN SEVERE PNEUMONIA WITH HYPERLEUKOCYTOSIS 86
TABLE 22 US-ADJUSTED RECIPROCAL TARIFF RATES, 2024 88
TABLE 23 KEY PRODUCT-RELATED TARIFF EFFECTIVE 88
TABLE 24 NORTH AMERICA: IMPACT OF US TARIFFS 89
TABLE 25 ASIA PACIFIC: IMPACT OF US TARIFFS 89
TABLE 26 EUROPE: IMPACT OF US TARIFFS 90
TABLE 27 LATIN AMERICA: IMPACT OF US TARIFFS 91
TABLE 28 LEUKAPHERESIS MARKET: KEY PATENTS, 2023–2025 98
TABLE 29 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 30 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 31 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 32 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 33 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS 110
TABLE 35 KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE 111
TABLE 36 LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 116
TABLE 37 DISPOSABLES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE
2024–2031 (USD MILLION) 117
TABLE 38 LEUKAPHERESIS DISPOSABLE PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 117
TABLE 39 TUBING SETS & COLLECTION BAGS MARKET, BY TYPE, 2024–2031 (USD MILLION) 118
TABLE 40 COMMERCIALLY AVAILABLE FILTERS & MEMBRANE CONSUMABLES 120
TABLE 41 FILTERS & MEMBRANE CONSUMABLES MARKET, BY TYPE,
2024–2031 (USD MILLION) 120
TABLE 42 COMMERCIALLY AVAILABLE COLLECTION KITS & ACCESSORIES 121
TABLE 43 COLLECTION KITS & ACCESSORIES MARKET, BY TYPE,2024–2031 (USD MILLION) 122
TABLE 44 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 123
TABLE 45 CENTRIFUGAL DEVICES AVAILABLE 125
TABLE 46 CENTRIFUGAL DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 47 CENTRIFUGAL DEVICES VOLUME MARKET, 2024–2031 (UNITS SOLD) 126
TABLE 48 MEMBRANE SEPARATORS AVAILABLE 127
TABLE 49 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 50 LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 130
TABLE 51 COMPANIES DEVELOPING FDA-APPROVED CAR-T CELL THERAPIES 131
TABLE 52 LEUKAPHERESIS MARKET IN RESEARCH APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 131
TABLE 53 LEUKAPHERESIS MARKET IN THERAPEUTIC APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 54 LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 135
TABLE 55 LEUKAPHERESIS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 56 LEUKAPHERESIS MARKET FOR HOSPITALS & TRANSFUSION CENTERS,
BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 57 LEUKAPHERESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 58 CAR-T CELL THERAPY UNDER CLINICAL TRIALS 141
TABLE 59 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 60 LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 144
TABLE 61 LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 62 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 63 MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION,
2024–2031 (NO. OF BAGS) 148
TABLE 64 NUMBER OF CELLS IN NON-MOBILIZED LEUKOPAKS 148
TABLE 65 COMPARATIVE ANALYSIS OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 149
TABLE 66 COMPOSITION OF MOBILIZED AND NON-MOBILIZED LEUKOPAKS 149
TABLE 67 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 68 NON-MOBILIZED LEUKOPAKS MARKET VOLUME, BY REGION,
2024–2031 (NO. OF BAGS) 151
TABLE 69 DISEASED CELL LEUKOPAKS AND THEIR ROLE IN CELL THERAPY 152
TABLE 70 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 71 DISEASED LEUKOPAKS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS) 153
TABLE 72 IMMUNE CELL TYPES AND TARGETED DISEASES 154
TABLE 73 ISOLATED PBMCS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 74 ISOLATED PBMCS MARKET VOLUME, BY REGION, 2024–2031 (NO. OF BAGS) 156
TABLE 75 LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 159
TABLE 76 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY,
2024–2031 (USD MILLION) 160
TABLE 77 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY,
2024–2031 (USD MILLION) 161
TABLE 78 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 79 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 80 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 166
TABLE 81 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 82 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 83 LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 171
TABLE 84 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 85 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,
BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 86 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 87 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 88 LEUKOPAKS MARKET, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 89 MAJOR LEUKAPHERESIS MARKET PLAYERS IN NORTH AMERICA 180
TABLE 90 NORTH AMERICA: LEUKAPHERESIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 181
TABLE 91 NORTH AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 182
TABLE 92 NORTH AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 182
TABLE 93 NORTH AMERICA: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 182
TABLE 94 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 95 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 183
TABLE 96 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 184
TABLE 97 US: KEY MACROINDICATORS 185
TABLE 98 US: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 186
TABLE 99 US: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186
TABLE 100 US: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 186
TABLE 101 US: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 102 US: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 187
TABLE 103 US: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 188
TABLE 104 CANADA: KEY MACROINDICATORS 188
TABLE 105 CANADA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 189
TABLE 106 CANADA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 189
TABLE 107 CANADA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 189
TABLE 108 CANADA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 109 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 190
TABLE 110 CANADA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 191
TABLE 111 EUROPE: LEUKOPAKS MARKET, BY LEUKOPAK TYPE,
2024–2031 (MILLION UNIT BAGS) 192
TABLE 112 EUROPE: LEUKAPHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 113 EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 193
TABLE 114 EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 193
TABLE 115 EUROPE: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 194
TABLE 116 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 117 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 195
TABLE 118 EUROPE: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 195
TABLE 119 GERMANY: KEY MACROINDICATORS 197
TABLE 120 GERMANY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 197
TABLE 121 GERMANY: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 197
TABLE 122 GERMANY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 198
TABLE 123 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 199
TABLE 125 GERMANY: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 199
TABLE 126 UK: KEY MACROINDICATORS 200
TABLE 127 UK: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 200
TABLE 128 UK: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 200
TABLE 129 UK: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 201
TABLE 130 UK: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 131 UK: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 202
TABLE 132 UK: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 202
TABLE 133 FRANCE: KEY MACROINDICATORS 203
TABLE 134 SPAIN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 203
TABLE 135 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 136 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 204
TABLE 137 SPAIN: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 205
TABLE 138 ITALY: KEY MACROINDICATORS 205
TABLE 139 ITALY: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 206
TABLE 140 ITALY: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 206
TABLE 141 ITALY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 206
TABLE 142 ITALY: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 143 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 207
TABLE 144 ITALY: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 208
TABLE 145 SPAIN: KEY MACROINDICATORS 208
TABLE 146 NETHERLANDS: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 210
TABLE 147 NETHERLANDS: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 210
TABLE 148 NETHERLANDS: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 210
TABLE 149 NETHERLANDS: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 150 NETHERLANDS: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 211
TABLE 151 NETHERLANDS: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 212
TABLE 152 POLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 212
TABLE 153 POLAND: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213
TABLE 154 POLAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 213
TABLE 155 POLAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 156 POLAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 214
TABLE 157 POLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 214
TABLE 158 SWITZERLAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 215
TABLE 159 SWITZERLAND: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 215
TABLE 160 SWITZERLAND: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 216
TABLE 161 SWITZERLAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 162 SWITZERLAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 217
TABLE 163 SWITZERLAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 217
TABLE 164 REST OF EUROPE: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 218
TABLE 165 REST OF EUROPE: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 218
TABLE 166 REST OF EUROPE: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 218
TABLE 167 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 168 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 219
TABLE 169 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 170 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 222
TABLE 171 ASIA PACIFIC: LEUKOPAK PRODUCTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 223
TABLE 172 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 223
TABLE 173 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 223
TABLE 174 ASIA PACIFIC: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 224
TABLE 175 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 176 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 177 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 225
TABLE 178 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 226
TABLE 179 ASIA PACIFIC: LEUKOPAKS MARKET, BY LEUKOPAK TYPE,
2024–2031 (MILLION UNIT BAGS) 226
TABLE 180 CHINA: KEY MACROINDICATORS 228
TABLE 181 CHINA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 228
TABLE 182 CHINA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 228
TABLE 183 CHINA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 229
TABLE 184 CHINA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 185 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 230
TABLE 186 CHINA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 230
TABLE 187 JAPAN: KEY MACROINDICATORS 231
TABLE 188 JAPAN: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 232
TABLE 189 JAPAN: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 232
TABLE 190 JAPAN: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 232
TABLE 191 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 192 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 233
TABLE 193 JAPAN: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 234
TABLE 194 INDIA: KEY MACROINDICATORS 235
TABLE 195 INDIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 235
TABLE 196 INDIA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236
TABLE 197 INDIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 236
TABLE 198 INDIA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 199 INDIA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 237
TABLE 200 INDIA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 237
TABLE 201 AUSTRALIA: KEY MACROINDICATORS 239
TABLE 202 AUSTRALIA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 239
TABLE 203 AUSTRALIA: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 239
TABLE 204 AUSTRALIA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 240
TABLE 205 AUSTRALIA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 206 AUSTRALIA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 241
TABLE 207 AUSTRALIA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 241
TABLE 208 SOUTH KOREA: KEY MACROINDICATORS 242
TABLE 209 SOUTH KOREA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 243
TABLE 210 SOUTH KOREA: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 243
TABLE 211 SOUTH KOREA: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 243
TABLE 212 SOUTH KOREA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 213 SOUTH KOREA: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 244
TABLE 214 SOUTH KOREA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 244
TABLE 215 NEW ZEALAND: KEY MACROINDICATORS 245
TABLE 216 NEW ZEALAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 246
TABLE 217 NEW ZEALAND: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 246
TABLE 218 NEW ZEALAND: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 246
TABLE 219 NEW ZEALAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 220 NEW ZEALAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 247
TABLE 221 NEW ZEALAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 248
TABLE 222 THAILAND: KEY MACROINDICATORS 249
TABLE 223 THAILAND: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 249
TABLE 224 THAILAND: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 249
TABLE 225 THAILAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 250
TABLE 226 THAILAND: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 227 THAILAND: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 251
TABLE 228 THAILAND: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 251
TABLE 229 ROAPAC: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 252
TABLE 230 ROAPAC: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252
TABLE 231 ROAPAC: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 253
TABLE 232 ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 233 ROAPAC: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 254
TABLE 234 ROAPAC: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 254
TABLE 235 LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 255
TABLE 236 LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 255
TABLE 237 LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 256
TABLE 238 LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 239 LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 257
TABLE 240 LATIN AMERICA: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 257
TABLE 241 BRAZIL: KEY MACROINDICATORS 259
TABLE 242 BRAZIL: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 259
TABLE 243 BRAZIL: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 260
TABLE 244 BRAZIL: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 260
TABLE 245 BRAZIL: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 246 BRAZIL: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 261
TABLE 247 BRAZIL: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 261
TABLE 248 MEXICO: KEY MACROINDICATORS 262
TABLE 249 MEXICO: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 262
TABLE 250 MEXICO: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 263
TABLE 251 MEXICO: LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 263
TABLE 252 MEXICO: LEUKOPAKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 253 MEXICO: LEUKOPAKS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 264
TABLE 254 MEXICO: LEUKOPAKS MARKET, BY END USER, 2024–2031 (USD MILLION) 264
TABLE 255 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 265
TABLE 256 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 265
TABLE 257 REST OF LATIN AMERICA: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 266
TABLE 258 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 266
TABLE 259 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 267
TABLE 260 REST OF LATIN AMERICA: LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 267
TABLE 261 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 269
TABLE 262 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 269
TABLE 263 MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 269
TABLE 264 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 265 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 270
TABLE 266 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 271
TABLE 267 MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY LEUKOPAK TYPE,
2024–2031 (MILLION UNIT BAGS) 271
TABLE 268 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 273
TABLE 269 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 273
TABLE 270 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274
TABLE 271 KINGDOM OF SAUDI ARABIA (KSA): LEUKAPHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 274
TABLE 272 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 274
TABLE 273 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 275
TABLE 274 KINGDOM OF SAUDI ARABIA (KSA): LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 275
TABLE 275 UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS 276
TABLE 276 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 276
TABLE 277 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277
TABLE 278 UNITED ARAB EMIRATES (UAE): LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 277
TABLE 279 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 277
TABLE 280 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 278
TABLE 281 UNITED ARAB EMIRATES (UAE): LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 278
TABLE 282 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 279
TABLE 283 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 279
TABLE 284 OTHER GCC COUNTRIES: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 280
TABLE 285 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 286 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 281
TABLE 287 OTHER GCC COUNTRIES: LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 281
TABLE 288 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 282
TABLE 289 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282
TABLE 290 REST OF MIDDLE EAST & AFRICA: LEUKAPHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 283
TABLE 291 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY TYPE,
2024–2031 (USD MILLION) 283
TABLE 292 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 284
TABLE 293 REST OF MIDDLE EAST & AFRICA: LEUKOPAKS MARKET, BY END USER,
2024–2031 (USD MILLION) 284
TABLE 294 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, JANUARY 2023–MARCH 2026 286
TABLE 295 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN LEUKOPAKS MARKET, JANUARY 2023–MARCH 2026 287
TABLE 296 LEUKAPHERESIS MARKET: DEGREE OF COMPETITION 290
TABLE 297 LEUKOPAKS MARKET: DEGREE OF COMPETITION 292
TABLE 298 LEUKOPAKS MARKET: REGION FOOTPRINT 294
TABLE 299 LEUKOPAKS MARKET: BY PRODUCT TYPE FOOTPRINT 295
TABLE 300 LEUKOPAKS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 297
TABLE 301 LEUKOPAKS MARKET: COMPETITIVE BENCHMARKING OF KEY
STARTUP/SME PLAYERS 298
TABLE 302 LEUKAPHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 303
TABLE 303 LEUKAPHERESIS MARKET: DEALS, JANUARY 2023–MARCH 2026 304
TABLE 304 LEUKAPHERESIS MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 305
TABLE 305 LEUKOPAKS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 305
TABLE 306 LEUKOPAKS MARKET: DEALS, JANUARY 2023–MARCH 2026 307
TABLE 307 LEUKOPAKS MARKET: EXPANSIONS, JANUARY 2023–MARCH 2026 309
TABLE 308 TERUMO CORPORATION: COMPANY OVERVIEW 311
TABLE 309 TERUMO CORPORATION: PRODUCTS OFFERED 312
TABLE 310 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 314
TABLE 311 TERUMO CORPORATION: DEALS, JANUARY 2023–MARCH 2026 314
TABLE 312 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 315
TABLE 313 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 317
TABLE 314 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 318
TABLE 315 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 319
TABLE 316 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MARCH 2026 320
TABLE 317 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS,
JANUARY 2023–MARCH 2026 320
TABLE 318 HAEMONETICS CORPORATION: COMPANY OVERVIEW 322
TABLE 319 HAEMONETICS CORPORATION: PRODUCTS OFFERED 323
TABLE 320 HAEMONETICS CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 326
TABLE 321 HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MARCH 2026 326
TABLE 322 NIKKISO CO., LTD.: COMPANY OVERVIEW 328
TABLE 323 NIKKISO CO., LTD.: PRODUCTS OFFERED 329
TABLE 324 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 330
TABLE 325 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW 331
TABLE 326 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED 332
TABLE 327 DANAHER CORPORATION: COMPANY OVERVIEW 334
TABLE 328 DANAHER CORPORATION: PRODUCTS OFFERED 335
TABLE 329 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW 336
TABLE 330 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED 337
TABLE 331 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW 338
TABLE 332 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED 338
TABLE 333 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS,
JANUARY 2023–MARCH 2026 339
TABLE 334 MACOPHARMA SA: COMPANY OVERVIEW 340
TABLE 335 MACOPHARMA SA: PRODUCTS OFFERED 340
TABLE 336 MEDICA SPA: COMPANY OVERVIEW 342
TABLE 337 MEDICA SPA: PRODUCTS OFFERED 342
TABLE 338 POLYMED: COMPANY OVERVIEW 343
TABLE 339 PURIBLOOD MEDICAL: COMPANY OVERVIEW 344
TABLE 340 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.:
COMPANY OVERVIEW 345
TABLE 341 SAFETRAN BIOMEDICAL INC.: COMPANY OVERVIEW 346
TABLE 342 MITRA INDUSTRIES PRIVATE LIMITED: COMPANY OVERVIEW 347
TABLE 343 LONZA: COMPANY OVERVIEW 348
TABLE 344 LONZA: PRODUCTS OFFERED 349
TABLE 345 LONZA: DEALS, JANUARY 2023–MARCH 2026 351
TABLE 346 GRIFOLS: COMPANY OVERVIEW 352
TABLE 347 GRIFOLS: PRODUCTS OFFERED 353
TABLE 348 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW 355
TABLE 349 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED 356
TABLE 350 CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 358
TABLE 351 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–MARCH 2026 358
TABLE 352 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2023–MARCH 2026 359
TABLE 353 CELLEX CELL PROFESSIONALS: COMPANY OVERVIEW 360
TABLE 354 CELLEX CELL PROFESSIONALS: PRODUCTS OFFERED 361
TABLE 355 CELLEX CELL PROFESSIONALS: DEALS, JANUARY 2023–MARCH 2026 361
TABLE 356 CELLEX CELLS PROFESSIONALS: EXPANSIONS, JANUARY 2023–MARCH 2026 362
TABLE 357 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 363
TABLE 358 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED 363
TABLE 359 BIOIVT: COMPANY OVERVIEW 365
TABLE 360 BIOIVT: PRODUCTS OFFERED 365
TABLE 361 BIOIVT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 367
TABLE 362 BIOIVT: DEALS, JANUARY 2023–MARCH 2026 367
TABLE 363 BIOIVT: EXPANSIONS, JANUARY 2023–MARCH 2026 367
TABLE 364 DISCOVERY LIFE SCIENCES: COMPANY OVERVIEW 368
TABLE 365 DISCOVERY LIFE SCIENCES: PRODUCTS OFFERED 368
TABLE 366 DISCOVERY LIFE SCIENCES: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 370
TABLE 367 DISCOVERY LIFE SCIENCES: DEALS, JANUARY 2023–MARCH 2026 370
TABLE 368 DISCOVERY LIFE SCIENCES: EXPANSIONS, JANUARY 2023–MARCH 2026 370
TABLE 369 MILTENYI BIOTEC: COMPANY OVERVIEW 371
TABLE 370 MILTENYI BIOTEC: PRODUCTS OFFERED 372
TABLE 371 STEMVIVO INC.: COMPANY OVERVIEW 373
TABLE 372 STEMVIVO INC.: PRODUCTS OFFERED 374
TABLE 373 CGT GLOBAL: COMPANY OVERVIEW 375
TABLE 374 CGT GLOBAL: PRODUCTS OFFERED 375
TABLE 375 CGT GLOBAL: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MARCH 2026 377
TABLE 376 SANGUINE BIOSCIENCES: COMPANY OVERVIEW 378
TABLE 377 SANGUINE BIOSCIENCES: PRODUCTS OFFERED 378
TABLE 378 SANGUINE BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MARCH 2026 379
TABLE 379 BIOMEX GMBH: COMPANY OVERVIEW 380
TABLE 380 ACCEGEN: COMPANY OVERVIEW 381
TABLE 381 EXCELLOS: COMPANY OVERVIEW 382
TABLE 382 FIRST CHOICE BIO INC.: COMPANY OVERVIEW 383
TABLE 383 ORGANA BIO: COMPANY OVERVIEW 384
TABLE 384 HUMAN CELLS BIO: COMPANY OVERVIEW 384
TABLE 385 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON
LEUKAPHERESIS MARKET 395
TABLE 386 RISK ASSESSMENT: LEUKAPHERESIS MARKET 398

LIST OF FIGURES

FIGURE 1 LEUKAPHERESIS MARKET: SEGMENTATION & REGIONAL SCOPE 33
FIGURE 2 LEUKAPHERESIS MARKET: YEARS CONSIDERED 35
FIGURE 3 MARKET SCENARIO 38
FIGURE 4 LEUKAPHERESIS MARKET, 2026–2031 39
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKOPAKS
MARKET, 2024–2026 39
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LEUKAPHERESIS MARKET, 2024–2026 40
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF LEUKAPHERESIS MARKET 41
FIGURE 8 HIGH-GROWTH SEGMENTS IN LEUKOPAKS MARKET, 2026–2031 42
FIGURE 9 HIGH-GROWTH SEGMENTS IN LEUKAPHERESIS MARKET, 2026–2031 42
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKAPHERESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 43
FIGURE 11 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LEUKOPAKS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 44
FIGURE 12 GROWING INCIDENCE OF CANCER TO DRIVE MARKET 45
FIGURE 13 BLOOD COMPONENT PROVIDERS AND BLOOD CENTERS SEGMENT
AND JAPAN ACCOUNTED FOR LARGEST MARKET SHARES IN 2025 46
FIGURE 14 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 47
FIGURE 15 GROWING PREVALENCE OF LEUKEMIA AND ADOPTION OF CAR T-CELL
THERAPY TO DRIVE MARKET 48
FIGURE 16 MOBILIZED LEUKOPAKS SEGMENT AND CHINA ACCOUNTED FOR LARGEST MARKET SHARES IN 2025 49
FIGURE 17 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 50
FIGURE 18 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
FIGURE 19 ESTIMATED NUMBER OF NEW LEUKEMIA CASES, BY REGION (2020 VS. 2040) 53
FIGURE 20 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020 VS. 2040) 53
FIGURE 21 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 66
FIGURE 22 LEUKAPHERESIS MARKET: SUPPLY CHAIN ANALYSIS 70
FIGURE 23 LEUKAPHERESIS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 24 LEUKOPAKS MARKET: VALUE CHAIN ANALYSIS 72
FIGURE 25 LEUKAPHERESIS MARKET ECOSYSTEM 74
FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN
LEUKAPHERESIS MARKET 83
FIGURE 27 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN
LEUKOPAKS MARKET 84
FIGURE 28 INVESTMENT & FUNDING SCENARIO FOR LEUKAPHERESIS MARKET PLAYERS 85
FIGURE 29 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKAPHERESIS PATENTS (JANUARY 2015–MARCH 2026) 98
FIGURE 30 LEUKAPHERESIS MARKET: AI USE CASES 102
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LEUKOPAKS 110
FIGURE 32 KEY BUYING CRITERIA FOR LEUKOPAKS, BY TYPE 111
FIGURE 33 NORTH AMERICA: LEUKAPHERESIS MARKET SNAPSHOT 181
FIGURE 34 NORTH AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE,
2024–2031 (NO. OF BAGS) 184
FIGURE 35 EUROPE VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 196
FIGURE 36 ASIA PACIFIC: LEUKAPHERESIS MARKET SNAPSHOT 222
FIGURE 37 ASIA PACIFIC VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 226
FIGURE 38 LATIN AMERICA VOLUME ANALYSIS: LEUKOPAKS TYPE, 2024–2031 (NO. OF BAGS) 258
FIGURE 39 MIDDLE EAST & AFRICA VOLUME ANALYSIS: LEUKOPAKS TYPE,
2024–2031 (NO. OF BAGS) 272
FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2023–2025 288
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2023–2025 289
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKAPHERESIS MARKET, 2025 290
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LEUKOPAKS MARKET, 2025 291
FIGURE 44 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 293
FIGURE 45 LEUKOPAKS MARKET: COMPANY FOOTPRINT 294
FIGURE 46 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 296
FIGURE 47 EV/EBITDA OF KEY VENDORS FOR LEUKAPHERESIS 298
FIGURE 48 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKAPHERESIS 299
FIGURE 49 EV/EBITDA OF KEY VENDORS FOR LEUKOPAKS 299
FIGURE 50 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR LEUKOPAKS 300
FIGURE 51 LEUKOPAKS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 301
FIGURE 52 LEUKAPHERESIS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 302
FIGURE 53 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 312
FIGURE 54 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025) 318
FIGURE 55 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025) 323
FIGURE 56 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025) 329
FIGURE 57 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025) 332
FIGURE 58 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 335
FIGURE 59 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2025) 337
FIGURE 60 LONZA: COMPANY SNAPSHOT (2025) 349
FIGURE 61 GRIFOLS: COMPANY SNAPSHOT (2025) 353
FIGURE 62 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.:
COMPANY SNAPSHOT (2025) 356
FIGURE 63 LEUKAPHERESIS MARKET: RESEARCH DESIGN 386
FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET) 389
FIGURE 65 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET) 389
FIGURE 66 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKAPHERESIS MARKET) 390
FIGURE 67 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET) 390
FIGURE 68 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION (LEUKOPAKS MARKET) 391
FIGURE 69 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 392
FIGURE 70 REVENUE SHARE ANALYSIS ILLUSTRATION: TERUMO CORPORATION (2025) 392
FIGURE 71 DEMAND-SIDE APPROACH: LEUKAPHERESIS MARKET (2025) 393
FIGURE 72 LEUKAPHERESIS MARKET: CAGR PROJECTIONS (2026–2031) 394
FIGURE 73 TOP-DOWN APPROACH 395
FIGURE 74 DATA TRIANGULATION METHODOLOGY 396

---

---